Red Flags Detected
- Securities Litigation (new) — Federal class action filed alleging material misstatements about briquilimab clinical trials, followed by two derivative suits against officers and directors.
- Going Concern (new) — Company now discloses substantial doubt about ability to continue as going concern beyond one year from filing date due to insufficient cash under current operating plan.
Jasper faces securities litigation, going-concern warning as cash drops 71% to $14M
Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2025 · ~2 min read
Key Changes
-
high
Federal securities class action filed September 2025 alleging material misstatements about briquilimab clinical trials; two derivative suits followed. Company filed motion to dismiss but cannot estimate potential losses or accrual amounts.
Legal Proceedings verify on EDGAR → -
high
Cash declined from $48.8M to $14.1M year-over-year; company discloses 'imminent need' for additional funding and 'substantial doubt' about ability to continue as going concern beyond twelve months from filing date.
MD&A: Liquidity verify on EDGAR → -
high
Public float fell below $75M, triggering SEC rule limiting shelf-based fundraising to one-third of float in any twelve-month period. Company raised $27.5M in September 2025 offering but issued 12.3M warrants representing substantial future dilution.
Risk Factors: Capital Raising verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.
Partner
Trade JSPRW commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 10, 2026 9:24 PM